We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
Read MoreHide Full Article
Friday, January 11, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific (BSX - Free Report) , Southern Company (SO - Free Report) and BNY Mellon (BK - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Boston Scientific’s shares have outperformed the Zacks Medical Products industry over the past three months, losing -2.8% vs. -8.5%. The Zacks analyst thinks the company is suffering from significant cost escalation, which is weighing on its margins.
Also, a delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group.
This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. Three recent acquisitions- Claret Medical, VENITI and Augmenix, provide cause for optimism. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch is also encouraging. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum.
Shares of Southern Company have underperformed the Zacks Electric Power industry over the past six months, losing -3.4% vs +2.7%. The Zacks analyst emphasizes that the company is one of the largest electric utility holding companies in the United States and has managed to surpass estimates in each of the last seven quarters.
The company’s $12-billion AGL Resources buyout has significantly increased its customer base and diversified offerings. With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts.
However, elevated leverage of the firm, along with continued timing and cost overrun issues over two of its major projects — Vogtle and Kemper — are major overhangs. While the company’s $25-billion Vogtle nuclear plant has already exceeded its budget and is years behind schedule, its Kemper project also suffered a setback with the suspension of all coal gasification operations amid additional cost burden. This is why Southern Company warrants a cautious stance from the investors.
BNY Mellon’s shares have outperformed the Zacks Major Regional Banks industry in the past year (-18.8% vs. -19.1%). The company’s earnings surpassed expectations in only two of the trailing four quarters. Further, the earnings estimates have been going downward ahead of the company’s fourth quarter results.
The Zacks analyst thinks elevated operating expenses will likely continue to hamper bottom line growth to some extent. Also, the concentration risk, arising from significant dependence on fee-based income, remains a matter of concern.
However, higher interest rates, increase in fee income and improving assets balance will support profitability. Further, enhanced capital deployment plan reflects strong balance sheet position.
Other noteworthy reports we are featuring today include Occidental Petroleum (OXY - Free Report) , Schlumberger (SLB - Free Report) and Southwest Airlines (LUV - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
Friday, January 11, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific (BSX - Free Report) , Southern Company (SO - Free Report) and BNY Mellon (BK - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Boston Scientific’s shares have outperformed the Zacks Medical Products industry over the past three months, losing -2.8% vs. -8.5%. The Zacks analyst thinks the company is suffering from significant cost escalation, which is weighing on its margins.
Also, a delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group.
This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. Three recent acquisitions- Claret Medical, VENITI and Augmenix, provide cause for optimism. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch is also encouraging. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum.
(You can read the full research report on Boston Scientific here >>>).
Shares of Southern Company have underperformed the Zacks Electric Power industry over the past six months, losing -3.4% vs +2.7%. The Zacks analyst emphasizes that the company is one of the largest electric utility holding companies in the United States and has managed to surpass estimates in each of the last seven quarters.
The company’s $12-billion AGL Resources buyout has significantly increased its customer base and diversified offerings. With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts.
However, elevated leverage of the firm, along with continued timing and cost overrun issues over two of its major projects — Vogtle and Kemper — are major overhangs. While the company’s $25-billion Vogtle nuclear plant has already exceeded its budget and is years behind schedule, its Kemper project also suffered a setback with the suspension of all coal gasification operations amid additional cost burden. This is why Southern Company warrants a cautious stance from the investors.
(You can read the full research report on Southern Company here >>>).
BNY Mellon’s shares have outperformed the Zacks Major Regional Banks industry in the past year (-18.8% vs. -19.1%). The company’s earnings surpassed expectations in only two of the trailing four quarters. Further, the earnings estimates have been going downward ahead of the company’s fourth quarter results.
The Zacks analyst thinks elevated operating expenses will likely continue to hamper bottom line growth to some extent. Also, the concentration risk, arising from significant dependence on fee-based income, remains a matter of concern.
However, higher interest rates, increase in fee income and improving assets balance will support profitability. Further, enhanced capital deployment plan reflects strong balance sheet position.
(You can read the full research report on BNY Mellon here >>>).
Other noteworthy reports we are featuring today include Occidental Petroleum (OXY - Free Report) , Schlumberger (SLB - Free Report) and Southwest Airlines (LUV - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>